logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

Stephen Van Deventer, chairman and CEO of PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) and chief research officer Dr Harry Parekh discuss with Proactive the health sciences specialist's four exciting programmes.

Their most advanced is centred around Cannabidiol (CBD) - a non-psychoactive compound found in the cannabis plant and is now widely used to treat chronic pain, multiple sclerosis and other conditions.

Some evidence even suggests it can prevent symptoms of Alzheimer’s and appears to promote the death of cancer cells.

Quick facts: PreveCeutical Medical Inc.

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 11/15/2019

2 min read